Beta thalassemia is an inherited blood disorder where your body produces little or no beta-globin, one of two protein chains needed to build hemoglobin, the molecule in red blood cells that carries oxygen. Over 350 different mutations in a single gene can cause it, and roughly 1.3 million people worldwide are living with the condition. Depending on which mutations you inherit, beta thalassemia ranges from a silent trait with no symptoms to a severe, life-threatening anemia requiring lifelong treatment.
How Beta Thalassemia Affects Red Blood Cells
Normal hemoglobin is built from four protein chains: two alpha-globin and two beta-globin. In beta thalassemia, mutations in the beta-globin gene (located on chromosome 11) reduce or completely shut down beta-globin production. The problem isn’t just that you end up with less hemoglobin. The real damage comes from what happens to all the leftover alpha chains that have no beta partner to bind with.
Without enough beta-globin, excess alpha chains clump together inside developing red blood cells. These clumps puncture cell membranes and trigger the release of harmful molecules called reactive oxygen species, which cause even more damage. Most of the affected red blood cells die before they ever leave the bone marrow, a process called ineffective erythropoiesis. The few that do make it into the bloodstream are fragile and break down faster than normal. The result is anemia from two directions: fewer red blood cells are produced, and those that are produced don’t last long.
Three Levels of Severity
Because you inherit one copy of the beta-globin gene from each parent, the severity of beta thalassemia depends on whether one or both copies carry mutations, and how severely those mutations reduce beta-globin output.
Beta Thalassemia Trait (Minor)
If only one gene copy is mutated, you’re a carrier. This is the mildest form. Most people with beta thalassemia trait have slightly small red blood cells and mild anemia that often goes unnoticed. It rarely causes symptoms or requires treatment, but it matters for family planning because you can pass the mutation to your children.
Beta Thalassemia Intermedia
When both gene copies are mutated but at least one still produces some beta-globin, the result is a moderate form. People with intermedia have more significant anemia and may need occasional blood transfusions during illness, infection, or pregnancy. Some eventually need regular transfusions as they age.
Beta Thalassemia Major (Cooley’s Anemia)
When both gene copies are severely mutated and produce little to no beta-globin, the result is the most serious form. Infants with beta thalassemia major appear healthy at birth because they still have fetal hemoglobin, but symptoms develop within the first one to two years of life as fetal hemoglobin naturally declines. Without treatment, the body tries to compensate by massively expanding bone marrow production, which leads to characteristic skeletal changes including widening of the facial bones. The spleen and liver enlarge as they attempt to filter out damaged red blood cells and produce new ones outside the bone marrow. Growth is stunted, and severe anemia becomes life-threatening.
Where It’s Most Common
Beta thalassemia is most prevalent in East Asia, Southeast Asia, the Mediterranean, and the Middle East. East Asia has the highest age-standardized prevalence at about 54 cases per 100,000 people, followed by Southeast Asia at roughly 43 per 100,000. The carrier trait is especially common in these regions because carrying one copy of a thalassemia mutation offers some protection against malaria, similar to the sickle cell trait. Migration has spread the gene worldwide, so beta thalassemia now appears in populations across Europe, the Americas, and beyond.
How It’s Diagnosed
A standard complete blood count often provides the first clue: small red blood cells with low hemoglobin content, a pattern that can look like iron deficiency. The key test is hemoglobin electrophoresis, which separates the different types of hemoglobin in your blood. In beta thalassemia carriers, a specific hemoglobin fraction called HbA2 is elevated above 3.5% (some populations use a cutoff of 4.0% for greater accuracy). People with beta thalassemia major typically show very high levels of fetal hemoglobin (HbF) because the body ramps up its production to compensate for the missing adult hemoglobin. Genetic testing can identify the exact mutation involved, which is useful for predicting severity and for screening family members.
Treatment for Transfusion-Dependent Patients
People with beta thalassemia major need regular blood transfusions, typically every two to four weeks, to maintain adequate hemoglobin levels. This keeps the severe anemia at bay and suppresses the body’s destructive attempts to overproduce red blood cells in the bone marrow. The transfusions themselves work well for managing anemia, but they introduce a serious secondary problem: iron overload.
Each unit of transfused blood contains iron, and the human body has no efficient way to excrete excess iron. Over time, iron accumulates in the heart, liver, and hormone-producing glands, causing organ damage that can be fatal. To prevent this, most transfusion-dependent patients take iron chelation therapy, medications given as a daily pill or as an injection under the skin that bind excess iron so the body can eliminate it. Chelation is a lifelong commitment and one of the most important factors in long-term survival.
Life Expectancy and Outlook
Survival for people with severe beta thalassemia has improved dramatically over the past few decades thanks to better transfusion protocols and chelation therapy, but the condition still shortens life. A large study from South India found that only about 50% of patients with severe thalassemia survived to age 27, and death rates in children under five were seven times higher than in the general population. Outcomes are significantly better in countries with well-resourced healthcare systems, where consistent access to safe blood products and chelation medications can extend survival into the 50s, 60s, and beyond. The main causes of early death remain iron-related heart failure and infections.
Gene Therapy: A Potential Cure
Two gene therapies are now approved for transfusion-dependent beta thalassemia, offering the possibility of a one-time treatment that eliminates the need for lifelong transfusions.
The first, sold as Zynteglo, works by adding a functional copy of a modified beta-globin gene into a patient’s own stem cells. In clinical trials, about 89% of patients with certain genotypes achieved complete transfusion independence after a single treatment, maintaining average hemoglobin levels around 11.7 g/dL, which is close to normal. For patients with the most severe genotype (two copies of the most disabling mutations), results were less consistent: about a third achieved full transfusion independence, while others saw their transfusion needs drop by roughly 73%.
The second, called Casgevy, uses CRISPR gene-editing technology with a different strategy. Instead of adding a new beta-globin gene, it reactivates the production of fetal hemoglobin, which the body normally shuts off after infancy. Among 52 transfusion-dependent patients who received a single infusion, 91% achieved transfusion independence. Patients typically stopped needing transfusions about five weeks after treatment.
Both therapies require a preparatory course of chemotherapy to clear existing bone marrow before the modified stem cells are infused, which means a hospital stay and a recovery period. They are expensive and currently available only at specialized centers.
Diet and Iron Management
For people with beta thalassemia who are not yet on regular transfusions, dietary iron management plays a meaningful role. Limiting red meat, pork, lamb, and liver helps reduce iron intake from the most absorbable dietary sources. Drinking black tea with meals can cut non-heme iron absorption by 40% to 90%, a simple habit that research supports for non-transfusion-dependent patients. Green tea taken with meals has also been shown to decrease liver iron concentration over 12 months when combined with chelation therapy.
Vitamin C increases iron absorption from plant-based foods, so people with thalassemia are generally advised not to take vitamin C supplements unless specifically directed to do so alongside chelation treatment, where a small dose (around 100 mg per day) can actually help the chelation medication work more effectively. For people already receiving regular transfusions, dietary iron restriction is less of a priority because the iron load from transfused blood far exceeds anything absorbed through food.